文献速递类风湿关节炎

Filgotinib(选择性JAK-1抑制剂)短期治疗类风湿关节炎的疗效、安全性、药代动力学和药效学:两项随机IIa期试验结果

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
PubMed 文献 · Arthritis Rheumatol · 2017-08-31

两项为期4周的探索性、双盲、安慰剂对照IIa期试验纳入127例对甲氨蝶呤(MTX)应答不足的类风湿关节炎(RA)患者,在稳定MTX方案基础上加用Filgotinib(100 mg每日两次或30、75、150、200、300 mg每日一次)或安慰剂,评估安全性、疗效、药代动力学(PK)和药效学(PD)。主要疗效终点为第4周达到ACR20缓解的患者数量和百分比。结果显示75-300 mg剂量组达到主要终点,起效早,ACR20应答率至第4周逐渐升高,DAS28-CRP下降,血清CRP及其他PD标志物显著持续改善;PK在30-300 mg范围内呈剂量比例;未观察到其他选择性较低JAK抑制剂常见的早期副作用(如贫血加重、肝转氨酶影响、LDL或总胆固醇升高),中性粒细胞有限下降但无中性粒细胞减少,无感染,总体耐受良好,药物相关事件多为轻中度且短暂,最常见为恶心。

要点

  • Filgotinib 75-300 mg在MTX应答不足的RA患者中第4周达到ACR20主要终点,起效早。
  • 未观察到贫血加重、肝转氨酶影响或LDL/总胆固醇升高,无感染,耐受良好。
  • 中性粒细胞有限下降但无中性粒细胞减少,符合JAK-1抑制的免疫调节效应。

核心结论

  • Filgotinib选择性抑制JAK-1在RA中显示初步疗效,且在这些探索性研究中安全性令人鼓舞。

研究设计与样本

  • 两项为期4周的探索性、双盲、安慰剂对照IIa期试验,纳入127例对MTX应答不足的RA患者,在稳定MTX方案基础上加用Filgotinib口服胶囊(100 mg每日两次或30、75、150、200、300 mg每日一次)或安慰剂。

主要发现

  • 75-300 mg剂量组达到主要终点,ACR20应答率至第4周逐渐升高,DAS28-CRP下降。
  • 血清CRP及其他PD标志物显著持续改善。
  • Filgotinib及其主要代谢物PK在30-300 mg范围内呈剂量比例。
  • 未观察到贫血加重、肝转氨酶影响、LDL或总胆固醇升高,无感染。
  • 中性粒细胞有限下降但无中性粒细胞减少;药物相关事件多为轻中度短暂,最常见为恶心。

关键数值与推荐

  • 主要疗效终点为第4周达到ACR20缓解的患者数量和百分比。
  • 75-300 mg剂量组达到主要终点。
  • PK在30-300 mg范围内呈剂量比例。

临床怎么用

  • 对于MTX应答不足的RA患者,Filgotinib 75-300 mg短期治疗可考虑作为联合MTX的潜在选择,但需进一步验证。
  • 治疗期间需关注恶心等轻中度短暂不良事件,中性粒细胞有限下降但无中性粒细胞减少。

局限性

  • 研究为为期4周的探索性IIa期试验,样本量有限。
  • 长期疗效和安全性尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: JAK inhibitors have shown efficacy in rheumatoid arthritis (RA). We undertook this study to test our hypothesis that selective inhibition of JAK-1 would combine good efficacy with a better safety profile compared with less selective JAK inhibitors. METHODS: In two 4-week exploratory, double-blind, placebo-controlled phase IIa trials, 127 RA patients with an insufficient response to methotrexate (MTX) received filgotinib (GLPG0634, GS-6034) oral capsules (100 mg twice daily or 30, 75, 150, 200, or 300 mg once daily) or placebo, added onto a stable regimen of MTX, to evaluate safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of filgotinib. The primary efficacy end point was the number and percentage of patients in each treatment group meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at week 4. RESULTS: Treatment with filgotinib at 75-300 mg met the primary end point and showed early onset of efficacy. ACR20 response rates progressively increased to week 4, and the Disease Activity Score in 28 joints using the C-reactive protein (CRP) level decreased. Marked and sustained improvements were observed in serum CRP level and other PD markers. The PK of filgotinib and its major metabolite was dose proportional over the 30-300 mg range. Early side effects seen with other less selective JAK inhibitors were not observed (e.g., there was no worsening of anemia [JAK-2 inhibition related], no effects on liver transaminases, and no increase in low-density lipoprotein or total cholesterol). A limited decrease in neutrophils without neutropenia was consistent with immunomodulatory effects through JAK-1 inhibition. There were no infections. Overall, filgotinib was well tolerated. Events related to study drug were mild or moderate and transient during therapy, and the most common such event was nausea. CONCLUSION: Selective inhibition of JAK-1 with filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Vanhoutte F, Mazur M, Voloshyn O, et al. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. Arthritis Rheumatol. 2017. PMID: 28622463. doi:10.1002/art.40186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。